KineMed and CHDI announce collaboration

June 1, 2012

LCGC Europe eNews

LCGC Europe eNews-06-01-2012, Volume 0, Issue 0

KineMed Inc., (Emeryville, California, USA) and CHDI Foundation (New York, USA) have announced a collaboration that will see KineMed?s isotopic labelling and dynamic proteomics platform be used to investigate the turnover rates of huntingtin protein.

KineMed Inc., (Emeryville, California, USA) and CHDI Foundation (New York, USA) have announced a collaboration that will see KineMed’s isotopic labelling and dynamic proteomics platform be used to investigate the turnover rates of huntingtin protein.

KineMed’s technology will be used to measure in vivo dynamics of the huntingtin protein and will allow assessment of the rate of metabolism of huntingtin protein as a function of polyQ length and whether or not investigational drugs are affecting its production and clearance. A mutant form of the protein plays a central role in the pathogenesis of Huntington’s disease.

Seung Kwak, PhD, director, Target Biology, CHDI, commented, “The application of KineMed’s technology will provide us with unique insights into central nervous system disease pathophysiology. We are excited and hopeful that this collaboration will help define the dynamics of the mutant protein in disease-relevant tissues, and ultimately help measure therapeutic efficacy for Huntington’s disease.”

Scott Turner, PhD, executive vice president of research and development at KineMed, said, “We are delighted to continue our collaboration with CHDI in an area that leverages our capabilities to understand the biology of neurodegenerative diseases with complex phenotypes.”

For more information please visit ref="http://www.kinemed.com">www.kinemed.com

Related Content:

News